Storys aus Heidelberg, Germany

09.11.2022 – 10:56
Heidelberger Druckmaschinen AG
HEIDELBERG continues growth, with significant improvement in sales and result for first half-year
Heidelberg, Germany (ots/PRNewswire) - - Half-year sales some 14 percent up on previous year at €1,120 million - Big improvement in EBITDA after six months, by around €30 million to €104 million (EBITDA margin: 9.2 percent) - Incoming orders after six months match high level in previous year - Order backlog exceeds €1 billion for first time in years - Forecast ...
mehr
26.04.2022 – 14:01
Novaliq GmbH
NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL® (0.1% CYCLOSPORINE OPHTHALMIC SOLUTION) AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational ...
mehr
21.12.2021 – 14:00
Novaliq GmbH
Novaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL (ESSENCE-2) of CyclASol® in Dry Eye Disease
Heidelberg, Germany and Cambridge, Mass (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug ...
mehr
16.12.2021 – 08:01
Novaliq GmbH
PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE'S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS
Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the ...
mehr
12.10.2021 – 09:00
Novaliq GmbH
Novaliq Receives EU Quality Management Certificate According To New Medical Device Regulation (MDR)
Heidelberg, Germany (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that it has implemented and applies a quality management system in accordance with Annex IX, Chapter I of the EU ...
mehr
09.06.2021 – 08:00
Heidelberger Druckmaschinen AG
Heidelberg expecting profitable growth in FY 2021/2022 and subsequent years
Heidelberg, Germany (ots/PRNewswire) - - Marked rise in demand and successful transformation program inspire confidence - Growth and increase in value for packaging printing, digital business models, business in China, and new technologies (such as wallboxes) - Outlook for FY 2021/2022 predicts rise in sales to at least EUR 2 billion, increase in EBITDA margin from 5 ...
mehr
24.12.2020 – 09:00
NEC Laboratories Europe GmbH
NEC Laboratories Europe's Unikraft Doubles Cloud Computing Efficiency with Groundbreaking Technology
Heidelberg, Germany (ots/PRNewswire) - NEC Laboratories Europe recently demonstrated the effectiveness of its Unikraft technology by doubling the data throughput on a NGINX web server while running on Amazon Web Services (AWS). This is compared to the same web server running on a Linux-based image. The result is equivalent to reducing server resource costs by half, as ...
mehr
08.12.2020 – 14:00
Novaliq GmbH
Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
Heidelberg, Germany (ots/PRNewswire) - - ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA) - Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial - Topline data expected in 2nd half 2021 ...
mehr